Kornimate/medical-research-clean huggingface dataset:
sonographic and laboratory evaluation of the thyroid gland in patients with systemic sclerosis

Conditions: Systemic Sclerosis; Hashimoto Thyroiditis; Thyroid Nodules

Summary: systemic sclerosis (ssc) is a systemic disease that involves various organs such as the skin, kidneys, gastrointestinal tract and lungs. dysfunction of the thyroid gland is prevalent in these patients and may be related to thyroid fibrosis or to thyroid autoimmune disease, i.e. hashimoto's thyroiditis. thyroid nodules are prevalent in the general population, although some reports suggest they might be more frequent in patients with ssc. hashimoto's thyroiditis, by itself, carries a higher risk for thyroid nodules and thyroid cancer. the aim of the study:to characterize sonographycally the thyroid gland of patients with ssc with and without hashimoto's disease

the study protocol fifty patients with ssc according to the current international classification will be included in the study. the patients, followed-up regularly in an out-patient clinic, will be tested for their thyroid function tests as well as the presence of thyroid auto antibodies. clinical data will be collected from their medical records. ultrasonographic examination of the thyroid gland will be performed by a single examiner. the gland will be characterized in detail with regards to its size and echotexture and cervical lymph nodes will be detected. the number and size of its nodules will be described as well as their echoic pattern (iso, hyperechoic or hypoechoic) calcifications (micro and macro), and borders status. large nodules (≥ 1 cm in diameter) or with malignancy- associated characteristics will be aspirated according to current clinical practice. treatment will be given according to the cytology diagnosis. thyroid hormone supplementation will be recommended when thyrotropin level \>8 miu/l or according to clinical judgment of the investigators.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of systemic sclerosis exclusion criteria: * non

Keywords: systemic sclerosis hashimoto thyroiditis thyroid nodules
a study to evaluate the safety and effect of the experimental drugs abt-450/ritonavir/abt-267 (abt-450/r/abt-267) and abt-333 in subjects with chronic hepatitis c

Conditions: Chronic Hepatitis C Infection

Summary: the purpose of this study is to evaluate the safety and antiviral activity of abt-450/ritonavir/abt-267 (abt-450/r/abt-267; abt-450 also known as paritaprevir; abt-267 also known as ombitasvir) and abt-333 (also known as dasabuvir) with and without ribavirin (rbv) in patients with chronic hepatitis c virus genotype 1b (hcv gt1b) infection without cirrhosis.

a randomized, open-label, multicenter study to evaluate the safety and antiviral activity of the combination of abt-450/ritonavir/abt-267 (abt-450/r/abt-267) and abt-333 with and without ribavirin (rbv) in treatment-experienced, noncirrhotic participants with chronic hepatitis c virus genotype 1b (hcv gt1b) infection.

Eligibility criteria:
inclusion criteria: * females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile * chronic hepatitis c, genotype 1b-infection (hcv rna level greater than or equal to 10,000 iu/ml at screening) * subject's hepatitis c virus genotype is subgenotype 1b at screening without co infection with any other genotype/subgenotype. exclusion criteria: * significant liver disease with any cause other than hcv as the primary cause * positive hepatitis b surface antigen or anti-human immunodeficiency virus antibody * positive screen for drugs or alcohol * use of contraindicated medications within 2 weeks of dosing

Keywords: hepatitis c virus hepatitis c genotype 1 hepatitis c interferon-free chronic hepatitis c ombitasvir ribavirin viekira pak dasabuvir paritaprevir
a predictive score for the ischemic etiology of a transient diplopia (vasco-dip)

Conditions: Diplopia

Summary: the transient diplopias (td) is defined by a short diplopia. their etiology may be ophthalmological, neurological non-ischemic or of ischemic origin. the difficulty is to recognize an ischemic mechanism which imposes emergency cares. a clinical score could help the clinician to recognize the etiology of the td .


Eligibility criteria:
inclusion criteria: * transient diplopia (i.e. less than 24 hours) during the last 8 days exclusion criteria: -
hemodialysis frequency and the calcification propensity of serum

Conditions: Hemodialysis; Anuria

Summary: the aim of this clinical research project is to test the hypothesis that daily dialysis has favorable effects on the calcification propensity of human serum, when determined by the investigators' newly developed in vitro serum test. the investigators' hypothesis is that shorter interdialytic intervals will result in an improved calcification propensity of serum. the determination of serum calcification has the potential to become a novel measure of dialysis quality in the future.

background the serum calcification test has been established and validated by a. pasch and coworkers, the expertise to perform the necessary statistical analyses is present in the investigator's department, all patient-related procedures necessary for this project are routinely performed in the investigator's department. objective does short daily hemodialysis strengthen the calcification-inhibitory forces inherent in hemodialysis patient sera, when compared to conventional three-times weekly hemodialysis? methods serum calcification test

Eligibility criteria:
inclusion criteria: * chronic hemodialysis \>3 months * anuria (\<100ml urine per day) * written informed consent exclusion criteria * citrate dialysis * significant fistula recirculation (\>15%) * infection

Keywords: renal dialysis
pediatric preoperative virtual reality program

Conditions: Surgery; Anxiety

Summary: does the introduction of a preparatory virtual reality (vr) program that is used in the home environment, have an effect on the anxiety level of children immediately before surgery, prior to administration of preoperative sedatives?

up to 60% of children who require elective surgery report significant anxiety in the preoperative setting. severe perioperative anxiety of a child poses a major challenge for the surgeon, since it is often accompanied by adverse behavioral and emotional reactions and associated with a complicated operative and postoperative course. the investigators have made the personal experience that informing the children ahead of time about what to expect in the hospital, decreases child anxiety and increases parent satisfaction. there is considerable debate on the best way how to inform children about what to expect during their hospital stay. the investigators had a virtual reality application developed that introduces the children to several aspects of the hospital environment. therefore, these children now ahead of time what they will experience during their hospital stay. the aim is to evaluate the effect of this preparatory virtual reality application on the anxiety level of children immediately before surgery.

Eligibility criteria:
inclusion criteria: 1. the child is between the age of 7 and 13 years 2. the child is undergoing an elective surgical procedure under general anesthesia 3. the child understands swiss german 4. the parent(s) understand(s) german 5. the parent(s) possess a smart phone 6. internet access is given 7. the patient information has been explained 8. informed consent is signed exclusion criteria: 1. the child has a hearing impairment 2. the child has neurologic disorder 3. the child requires postoperative intensive care 4. the child has previous experience of anesthesia 5. american society of anesthesiologists (asa) score of iii or greater

Keywords: virtual reality pediatric anxiety surgery anesthesia intervention exposure randomized controlled trial pediatric urology orthopedic surgery general pediatric surgery pediatric orthopedics
registry for end stage renal failure

Conditions: End Stage Renal Failure

Summary: the rein registry collects case record data from patients with end stage renal disease followed in french guiana. this allows to generate incidence and rates for terminal renal disease, mortality rates for each territory. the regional data are pooled in order to get national statistics for end stage renal disease and transplantation activity in order to adapt prevention to the main causes of renal failure and treatment and care infrastructure.


Eligibility criteria:
inclusion criteria: * end stage renal failure exclusion criteria: * refusal to participate

Keywords: renal transplant
enhanced housing placement assistance

Conditions: HIV/AIDS; Housing Problems

Summary: randomized controlled trial of housing placement assistance for homeless persons with hiv

approximately 800 persons living with hiv/aids (plwha) reside in hiv emergency single-room-occupancy (sro) hotels in new york city and do not have the ability to secure permanent housing on their own. the study evaluated a pilot program which fast-tracked plwha from hiv emergency sro hotels into permanent housing. the enhanced housing placement assistance (ehpa) program had three components: 1) active recruitment of emergency sro hotel residents with high need for housing; 2) assistance in the rapid (fast-track) acquisition of permanent housing; and 3) participation in a 12-month support services program designed to prevent plwha from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability. participants were randomly assigned to either 1) ehpa or 2) usual care, which included standard connections to services and housing programs offered by the new york city hiv/aids services administration (hasa), housing opportunities for persons with aids (hopwa), or ryan white services, and were followed over twelve months using a questionnaire developed with significant input from the target population of plwha residing in emergency sro hotels.

Eligibility criteria:
inclusion criteria: * person living with hiv in new york city * residing in an new york city hasa single-adult single-room-occupancy (sro) hotel exclusion criteria: * inability to provide informed consent * inability to complete survey in english or spanish

Keywords: hiv housing homelessness
effects of octreotide acetate on circulating levels of chromogranin a in advanced prostate cancer patients

Conditions: Prostate Cancer

Summary: the present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin a. the demonstration of an antisecretory effect of somatostatin analogs could offer a rationale for a large scale randomized study.


Eligibility criteria:
inclusion criteria: 1. male patients aged \>18 2. ecog performance status \< 3 3. patients with metastatic prostate cancer currently receiving 1st line hormonal therapy (lhrh agonists or surgical castration) and failing with raising serum psa 4. biochemical progression documented by three consecutively rising serum psa measurements, each separated from the other by at least 2 weeks, with the last measurement being 50% or greater than the nadir psa achieved after the last therapeutic maneuver (i.e. first line hormonal therapy noted above) 5. demonstrated tolerance to a test dose of s.c. octreotide acetate injection at visit 1 6. elevated (\> 40 u/l according to dako elisa kit) chromogranin a plasma levels documented by at least two consecutive measurements 7. liver function tests \< 2.5 uln, serum creatinine within normality 8. serum psa (50% increased value) above 4 ng/ml for patients with intact prostate and \> 0.8 ng/ml for post prostatectomy patients at study entry 9. immediate history of rising psa \< 10 months 10. castrate levels of testosterone (\< 30 ng/dl) 11. life expectancy of \> 6 months 12. signed informed consent prior to initiation of any procedure exclusion criteria: 1. prior chemotherapy or other systemic anticancer therapy except for lhrh agonists, and/or non-steroidal anti-androgens (eg, flutamide, bicalutamide or nilandron) 2. palliative radiotherapy less than 6 weeks (42 days) prior to planned entry date 3. other investigational drugs within the past 28 days 4. long-term (\> 3 months) treatment with proton pump inhibitors 5. uncontrolled blood hypertension 6. other malignancies within 5 years prior to study entry, except for curatively treated non-melanotic skin cancer 7. patients with another non-malignant disease which would confound the evaluation of the primary endpoints or prevent the patient from complying with the protocol

Keywords: hrpc octreotide lar cga
effects of proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition on arterial wall inflammation in patients with elevated lipoprotein(a) (lp(a))

Conditions: Subjects With Hyperlipidemia, Dyslipidemia

Summary: a study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (pcsk9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).


Eligibility criteria:
inclusion criteria: * fasting lipoprotein(a) (lp(a)) 50 mg/dl or more at screening 1 * fasting low-density lipoprotein-cholesterol (ldl-c) 100 mg/dl or more at screening 1 * lipid lowering therapy including statin dose unchanged for at least 8 weeks prior to screening * target-to-background ratio (tbr) maximum higher than 1.6 (either right, left carotid or thoracic aorta) on fluorodeoxyglucose-positron emission tomography/computed tomography (fdg-pet/ct). exclusion criteria: * currently receiving, or less than 4 weeks since receiving, treatment in another investigational device or drug study(ies), or participating in other investigational procedures * known diagnosis of diabetes mellitus or screening fasting serum glucose ≥ 126 mg/dl or hemoglobin a1c (hba1c) ≥ 6.5% * subject with a history of homozygous familial hypercholesterolemia * history of a cardiovascular event * subject currently undergoing lipid apheresis * known contraindications or limitations to fdg-pet/ ct (scanner weight limit, devices that can cause image artifacts, or carotid/aortic stents/grafts * subject has had exposure to investigational drugs targeting lp(a) within the last 12 months, prior to screening * other exclusion criteria may apply.

Keywords: hyperlipidemia dyslipidemia proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition arterial wall inflamation elevated lipoprotein a
study of efficacy of oxcarbazepine in therapy of bronchial asthma

Conditions: Bronchial Asthma

Summary: the purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.

effective therapy of asthma still remains quite serious problem. according gina definition, asthma is an inflammatory disorder. consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. but asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. but some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. if bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy. we performed a double-blind, placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma. oxcarbazepine is antiepileptic drug of new generation, produced by novartis, and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine. comparison: patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.

Eligibility criteria:
inclusion criteria: * bronchial asthma has been known at least for 1 year * absence of long-term remissions of asthma (lasting more than 1 month) * poorly controlled asthma, due to various reasons * non-smokers exclusion criteria: * presence of concomitant severe diseases * allergy or adverse reactions to carbamazepine or oxcarbazepine * abnormal baseline haematology, blood chemistry or urinalysis * current use of long-acting beta-agonists * age younger than 16 years old * long-term history of smoking * pregnancy or lactating

Keywords: bronchial asthma oxcarbazepine antiepileptic drug efficacy
ghrelin decreases insulin sensitivity

Conditions: Healthy Subjects

Summary: ghrelin administration increases appetite and, in rodents, induces weight gain. the aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

the current study is initiated in order to assess the impact of acute ghrelin administration on insulin resistance measured by a hyperinsulinemic euglycemic clamp. second, as free fatty acid is the predominant substrate during fasting, we aim to asses the effects of ghrelin on local and systemic lipolysis.

Eligibility criteria:
inclusion criteria: * healthy men, age \>= 18 yr age \< 50 yr, body mass index \< 27.5 kg/m2above or equal to 18 yr exclusion criteria: * any disease, use of prescribed medication, age \ = 50 yr
ultrasound-guided manual vacuum aspiration (usg-mva)

Conditions: Ultrasound-guided Manual Vacuum Aspiration; First Trimester Spontaneous Abortion

Summary: this is a retrospective study to review the current experience of usg-mva in hong kong and also evaluate the effectiveness of usg-mva in cytological analysis in the management of first trimester miscarriage.

miscarriage can be managed expectantly, medically or surgically. in cases where cytogenetic analysis is wanted, surgical evacuation is the ideal option as the poc is difficult to be obtained after medical evacuation. however, traditional surgical evacuation requires the procedure to be performed under general anesthesia using an electric vacuum aspiration (eva). moreover, the chorionic villi obtained via poc is often less intact and dispersed, making the identification and analysis difficult. manual vacuum aspiration (mva) was first introduced in 1973. the procedure is performed using a hand-held 60ml syringe to create the suction force and the intrauterine contents are aspirated using either a flexible or rigid cannula attached on it. the procedure can be performed in an outpatient setting with simple oral analgesics or conscious sedation given beforehand. the investigators have previously evaluated the acceptability and feasibility of the addition of ultrasound guidance during the procedure. the investigators found that ultrasound-guided manual vacuum aspiration (usg-mva) is an effective alternative treatment modality to medical and traditional surgical evacuation under general anesthesia for the management of first trimester delayed or incomplete miscarriage. the procedure has been introduced in our locality since 2015. since then, the investigators have performed more than 200 cases of usg-mva locally. however, the subsequent local experience of usg-mva and culture failure rate in the poc during cytological analysis obtained via this method remains limited in the literature.

Eligibility criteria:
inclusion criteria: * women 18 years old or above * women with miscarriage who are suitable candidates for usg-mva * first trimester delayed miscarriage ≤ 12 weeks of gestation * incomplete miscarriage with pog ≤ 5cm * hemodynamically stable * tolerates well with speculum examination exclusion criteria: * women who are not feasible for the usg-mva * cervical stenosis * fibroid uterus ≥12 weeks in size * known uterine malformation * bleeding disorder * suspicion of active infection * inability to tolerate pelvic examination * history of allergy to misprostol or same group of medications

Keywords: usg-mva ultrasound-guided manual vacuum aspiration miscarriage cytological analysis manual vacuum aspiration
sfa treatment and vascular functions

Conditions: Peripheral Arterial Disease; Claudication, Intermittent

Summary: endovascular treatment of the superficial femoral artery has a high initial success rate, but restenosis occurs in up to 60% of cases. while restoration of tissue perfusion is achieved, interventional strategies affect endothelial function. endothelial dysfunction is the pathophysiologic principle involved in the initiation and progression of arteriosclerosis. the aim of this study is to determine the impact of endovascular strategies in the superficial femoral artery on local and systemic endothelial and vascular function.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by rutherford 2, 3, 4, or 5 * planed peripheral intervention tasc a-c * subject must be between 40 and 85 years old * female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation * guidewire must cross lesion(s) within the true lumen, without a relevant sub-intimal course * vessel diameter ≥3.0 mm and ≤6.0 mm * willing to comply with the specified follow-up evaluation * written informed consent prior to any study procedures exclusion criteria: * lesions tasc d * angiographic evidence of thrombus within target vessel * thrombolysis within 72 hours prior to the index procedure * aneurysm in the femoral artery or popliteal artery * concomitant hepatic insufficiency, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy * unstable angina pectoris at the time of the enrollment * recent myocardial infarction or stroke \< 30 days prior to the index procedure * life expectancy less than 12 months * septicemia at the time of enrollment * known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb * known or suspected allergies or contraindications to aspirin, clopidogrel or heparin * presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure